Results
TMD, stomatitis, gingivitis, pain, tooth
ADVERSE EVENTS, GINGIVITIS, STOMATITIS
This study was conducted from January 2017 to September 2017. Forty patients provided written informed consent, and 35 patients met the inclusion criteria. We excluded a subject who received prohibitive combination therapy after completing a clinical trial, evaluating its effectiveness. Therefore, evaluation of effectiveness was performed for 34 patients and safety evaluation was performed for 35 patients. The mean age of the patients was 32.9 ± 14.2 years.Figure 
Before and after treatment with PJD-UNIT. Yellow arrows show the test tooth. PJD treatment was performed on cervix. HAP layer is transparent
Change in VAS and improvement rate of air pain
Change in VAS and improvement rate of scratch painNo severe adverse events or device malfunctions were observed. Minor adverse events were reported in 4 patients, with 2 developing stomatitis and 2 developing gingivitis (NCI CTCAE Grade 1). All of the patients recovered without treatment. We did not perform statistical analyses, as the number of cases was too small. Regarding spontaneous pain, the improvement rate was 89.5% for PJD treatment and 71.2% for TMD treatment. In addition, no change from baseline was observed in GI.